3.21
price up icon5.25%   0.16
 
loading
Schlusskurs vom Vortag:
$3.05
Offen:
$3.09
24-Stunden-Volumen:
632.08K
Relative Volume:
1.50
Marktkapitalisierung:
$45.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.94M
KGV:
-0.8359
EPS:
-3.84
Netto-Cashflow:
$-22.97M
1W Leistung:
+36.60%
1M Leistung:
+122.92%
6M Leistung:
-46.50%
1J Leistung:
-51.87%
1-Tages-Spanne:
Value
$3.0311
$3.40
1-Wochen-Bereich:
Value
$2.2908
$3.48
52-Wochen-Spanne:
Value
$1.11
$17.88

Annovis Bio Inc Stock (ANVS) Company Profile

Name
Firmenname
Annovis Bio Inc
Name
Telefon
484-875-3192
Name
Adresse
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Name
Mitarbeiter
6
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-11
Name
Neueste SEC-Einreichungen
Name
ANVS's Discussions on Twitter

Vergleichen Sie ANVS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ANVS
Annovis Bio Inc
3.21 45.79M 0 -40.94M -22.97M -3.84
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-10 Herabstufung D. Boral Capital Buy → Hold
2024-10-25 Hochstufung Maxim Group Hold → Buy
2023-12-29 Eingeleitet Canaccord Genuity Buy
2021-07-07 Bestätigt Maxim Group Buy

Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten

pulisher
Jun 06, 2025

Annovis Bio to Host Webcast on June 24, 2025, Featuring Updates on Phase 3 AD Trial and PD Program Development - MyChesCo

Jun 06, 2025
pulisher
Jun 06, 2025

Annovis Bio Inc. to Host Webcast on Alzheimer’s and Parkinson’s Programs Updates - citybuzz -

Jun 06, 2025
pulisher
Jun 05, 2025

Annovis to Host Webinar and Live Q&A on June 24, 2025 - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Annovis Bio, Inc. to Host Live Webcast on Neurodegenerative Disease Developments and Phase 3 Trial Updates - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

Annovis CEO Reveals Latest Alzheimer's Phase 3 Data and FDA Feedback on Parkinson's Program - Stock Titan

Jun 05, 2025
pulisher
Jun 04, 2025

Annovis Bio (ANVS) Stock Surges Over 28% | ANVS Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Acquires 10,846 Shares of Annovis Bio, Inc. (NYSE:ANVS) - Defense World

Jun 04, 2025
pulisher
Jun 02, 2025

Annovis Bio, Inc. (NYSE:ANVS) Shares Purchased by Jane Street Group LLC - Defense World

Jun 02, 2025
pulisher
May 28, 2025

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Annovis Bio, Inc. (ANVS) Investors and Encourages Investors to Contact the Firm Before October 18, 2021 - The Globe and Mail

May 28, 2025
pulisher
May 26, 2025

Down Syndrome Market: Epidemiology, Therapies, Companies, - openPR.com

May 26, 2025
pulisher
May 20, 2025

Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN

May 20, 2025
pulisher
May 20, 2025

Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress - MSN

May 20, 2025
pulisher
May 17, 2025

Canaccord Genuity Group Issues Pessimistic Forecast for Annovis Bio (NYSE:ANVS) Stock Price - Defense World

May 17, 2025
pulisher
May 16, 2025

Annovis Bio, Inc. (NYSE:ANVS) Given Average Recommendation of “Buy” by Brokerages - Defense World

May 16, 2025
pulisher
May 15, 2025

Annovis Bio (ANVS) Target Price Lowered as Phase 3 Alzheimer's T - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Canaccord cuts Annovis Bio stock target to $17; keeps Buy rating - Investing.com Australia

May 15, 2025
pulisher
May 15, 2025

Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga

May 15, 2025
pulisher
May 15, 2025

Annovis Bio (ANVS) Price Target Reduced by Canaccord Genuity | ANVS Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Annovis Bio Launches Phase 3 Alzheimer’s Trial, Expands Research Efforts - citybuzz -

May 15, 2025
pulisher
May 13, 2025

Annovis Bio Appoints New Principal Financial Officer - TipRanks

May 13, 2025
pulisher
May 13, 2025

Annovis Provides Corporate Updates And Reports First Quarter 2025 Financial Results - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Annovis Bio Inc. Provides Corporate Updates and Q1 2025 Financial Results, Initiates Pivotal Phase 3 Clinical Trial for Alzheimer’s Disease - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Annovis Bio's New Phase 3 Alzheimer's Drug Trial Targets Both Symptoms and Disease Modification - Stock Titan

May 13, 2025
pulisher
May 10, 2025

Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 06, 2025

Annovis Bio Appoints Hui Liu as Director of Biostatistics - MSN

May 06, 2025
pulisher
Apr 30, 2025

Annovis Bio Strengthens Research Team with Appointment of Hui Liu as Director of Biostatistics - citybuzz -

Apr 30, 2025
pulisher
Apr 29, 2025

Annovis Bio hires new director of biostatistics amid AD trial - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Annovis Bio Appoints Hui Liu As Director Of Biostatistics - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

Annovis Bio Bolsters Alzheimer's Phase 3 Trial Team: Statistics Expert Joins at Critical Stage - Stock Titan

Apr 29, 2025
pulisher
Apr 26, 2025

LAWSUITS FILED AGAINST SLQT, ANVS and VIEWJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 21, 2025

Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of “Buy” from Analysts - Defense World

Apr 21, 2025
pulisher
Apr 15, 2025

Head-To-Head Survey: Eterna Therapeutics (NASDAQ:ERNA) and Annovis Bio (NYSE:ANVS) - Defense World

Apr 15, 2025
pulisher
Apr 09, 2025

Annovis Bio stock plunges to 52-week low of $1.14 By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 09, 2025

Annovis Bio stock plunges to 52-week low of $1.14 - Investing.com

Apr 09, 2025
pulisher
Apr 09, 2025

Buntanetap shows early potential for Parkinson’s-related dementia - The Pharma Letter

Apr 09, 2025
pulisher
Apr 08, 2025

Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com

Apr 08, 2025
pulisher
Apr 03, 2025

Buntanetap for Parkinson’s disease - Parkinson's News Today

Apr 03, 2025
pulisher
Apr 02, 2025

Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MSN

Apr 02, 2025
pulisher
Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Annovis Bio Receives Non-Compliance Notice from NYSE - MSN

Mar 31, 2025

Finanzdaten der Annovis Bio Inc-Aktie (ANVS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
Kapitalisierung:     |  Volumen (24h):